Steponavičienė Laura, Gudavičienė Daiva, Briedienė Rūta, Petroška Donatas, Garnelytė Aušra
Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.
Department of Public Health, Institute of Health Sciences Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Acta Med Litu. 2018;25(2):66-75. doi: 10.6001/actamedica.v25i2.3759.
Encapsulated papillary carcinoma (EPC) is a rare entity of breast cancer accounting for approximately 1-2% of all breast tumours. There are no evidence-based guidelines for the treatment of EPC.
From the database of the National Centre of Pathology (NCP), we obtained pathology reports of 19 patients with histologically confirmed EPC, who were treated at the National Cancer Institute (NCI) in Vilnius, Lithuania, between July 2009 and July 2015. Demographic, diagnostic and treatment data were collected from medical records retrospectively.
During the indicated period, 19 patients with EPC were treated at the NCI. Three of them had pure EPC, they were 74 to 81 years of age at the time of diagnosis (mean 76.7 years, median 75 years); all of them are still alive and no disease progression has been observed. Seven patients had EPC associated with carcinoma . Nine patients had EPC associated with invasive breast ductal carcinoma. All patients underwent surgery, in most cases - wide local excision. Only one patient died.
EPC is a rare form of breast cancer and usually presents with an invasive breast carcinoma or carcinoma in postmenopausal women. Tumours have an excellent prognosis in the cases of pure EPC and in both EPC associated with carcinoma in situ (CIS) and invasive carcinoma.
囊内乳头状癌(EPC)是一种罕见的乳腺癌类型,约占所有乳腺肿瘤的1 - 2%。目前尚无基于证据的EPC治疗指南。
从国家病理中心(NCP)数据库中,我们获取了19例经组织学确诊为EPC患者的病理报告,这些患者于2009年7月至2015年7月在立陶宛维尔纽斯的国家癌症研究所(NCI)接受治疗。回顾性地从病历中收集人口统计学、诊断和治疗数据。
在指定期间,19例EPC患者在NCI接受治疗。其中3例为单纯EPC,诊断时年龄为74至81岁(平均76.7岁,中位数75岁);他们均存活,且未观察到疾病进展。7例患者的EPC与原位癌相关。9例患者的EPC与浸润性乳腺导管癌相关。所有患者均接受了手术,大多数情况下为广泛局部切除。仅1例患者死亡。
EPC是一种罕见的乳腺癌形式,通常在绝经后女性中与浸润性乳腺癌或原位癌同时出现。在单纯EPC以及与原位癌(CIS)和浸润癌相关的EPC病例中,肿瘤预后良好。